MDMA in humans: Factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress

Journal of Psychopharmacology

Volumn 20, Issue 2, 2006, Pages 147-163

  Parrott, Andy C ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Bioenergy; Cannabis; Cognition; Ecstasy; MDMA; Memory; Mood; Stress; Temperature

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABINOID; PSYCHEDELIC AGENT; SEROTONIN RECEPTOR AFFECTING AGENT;

AFFECT; BRAIN; CANNABIS ADDICTION; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; DRUG ABUSE; DRUG EFFECT; DRUG INTERACTION; ENERGY METABOLISM; HUMAN; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

AFFECT; AMPHETAMINE-RELATED DISORDERS; BRAIN; CANNABINOIDS; COGNITION DISORDERS; DRUG INTERACTIONS; ENERGY METABOLISM; HALLUCINOGENS; HUMANS; MARIJUANA ABUSE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; SEROTONIN AGENTS;

EID: 32844467877     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106063268     Document Type: Review

References (174)

1. Back-Madruga C, Boone K B, Chang L, Grob C S, Lee A, Nations H, Poland R E (2003) Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users. Clin Neuropsychol 17: 446-459.
2. Baggott M, Heifets B, Jones R T, Mendelson J, Sferios E, Zehnder J (2000) Chemical analysis of ecstasy pills. J Am Med Assn 284: 2190
3. Barrett S P, Gross S R, Garand I, Pihl R O. (2005) Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst Use Misuse. 40: 1525-1537
4. Bellis M A, Hughes K, Bennett A, Thomson R (2002) The role of an international nightlife resort in the proliferation of recreational drugs. Addiction 98: 1713-1721
5. Bolla K I, McCann U D, Ricaurte G A (1998) Memory impairment in abstinent MDMA ('ecstasy') users. Neurology 51: 1532-1537
6. Boys A, Marsden J, Strang J (2001) Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res 16: 457-469
7. Brecht M-L, von Mayrhauser C (2002) Differences between ecstasy using and nonusing methamphetamine users. J Psychoact Drugs 34: 215-223
8. Brown P L, Kiyakin E A (2004) Brain hyperthermia induced by MDMA ('ecstasy'): modulation by environmental conditions. Eur J Neurosci 20: 51-58
9. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M (2003) Long-term effects of 'ecstasy' use on serotonin transporters of the brain investigated by PET. J Nucl Med 44: 375-384
10. Butler G K L, Harrison K N (2005) Self-reported impulsivity and 'ecstasy' (MDMA) use. Proceedings of the Psychologist (in press)
11. Butler G K L, Montgomery A M J (2004) Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use. Drug Alc Depend 76: 55-62
12. Chang L (2001) Neuroimaging studies in chronic effects of MDMA/Ecstasy use. National Institute on Drug Abuse Symposium on MDMA/Ecstasy Research. 19-20 July, Bethesda, Maryland, USA. Programme abstract, p. 21
13. Cohen R S (1995) Subjective reports on the effects of the MDMA (Ecstasy) experience in humans. Prog Neuro-Psychopharmacol Biol Psychiat 19: 1137-1145
14. Colado M I, Camarero J, Mechan A O, Sanchez V, Esteban B, Elliott J M, Green A R (2001) A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') on dopamine neurones in mouse brain. Br J Pharmacol 134: 1711-1723
15. Cole J C, Sumnall H R (2003) Altered states: the clinical effects of Ecstasy. Pharmacol Therap 98: 35-58
16. Cole J C, Bailey M, Sumnall H R, Wagstaff G F, King L A (2002) The contents of ecstasy tablets: implications for the study of their long-term effects. Addiction 97: 1531-1536
17. Connor T J (2004) Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system. Immunology 111: 357-367
18. Cornish J L, Schahnawaz Z, Thompson M R, Wong S, Morley K C, Hunt G E, McGregor I S (2003) Heat increases 3,4-methylenedioxymethamphetamine administration and social effects in rats. Eur J Pharmacol 482: 339-341
19. Cottler L B, Womack S B, Compton W M, Ben-Abdallah A (2001) ecstasy abuse and dependence: applicability and reliability of DSM-IV criteria among adolescents and young adults. Hum Psychopharmacol 16: 599-606
20. Creighton F, Black D, Hyde C (1991) ecstasy psychosis and flashbacks. Br J Psychiat 159: 713-715
21. Croft R J, Mackay A J, Mills A T D, Gruzelier J G H (2001a) The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 153: 373-379
22. Croft R J, Mackay A J, Mills A T D, Gruzelier J G H (2001b) Electrophysiological evidence of serotonergic impairment in long-term MDMA ('Ecstasy') users. Amer J Psychiat 158: 1687-1692
23. Croxford J L (2003) Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17: 179-202
24. Curran V (2000) Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 42: 34-41
25. Curran H V, Travill R A (1997) Mood and cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): weekend 'high' followed by mid-week 'low'. Addiction 92: 821-831
26. Curran H V, Verheyden S L (2003) Altered response to tryptophan supplementation after long-terms abstention from MDMA (ecstasy) is highly correlated with human memory function. Psychopharmacology 169: 91-103
27. Curran H V, Rees H, Hoare T, Hoshi R, Bond A (2004) Empathy and aggression: two faces of ecstasy? A study of interpretive cognitive bias and mood change in ecstasy users. Psychopharmacology 173: 425-433
28. Dafters R (1995) Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav 58: 877-882
29. Dafters R I, Lynch E (1998) Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') but not by fenfluramine. Psychopharmacology 138: 207-212
30. Dafters R I, Hoshi R, Talbot A C (2004) Contribution of cannabis and MDMA ('ecstasy') to cognitive changes in long-term polydrug users. Psychopharmacology 173: 405-410
31. Dafters R I, Duffy F, O'Donnell P J, Bouquet C (1999) Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology, 145, 82-90
32. Darvesh A S, Gudelsky G A (2005) Evidence for a role of energy dysregulation in the MDMA-induced depletion of brain 5-HT. Brain Res 21: 168-175
33. Daumann J, Fischermann T, Heekeren K, Henke K, Thron A, Gouzoulis-Mayfrank E (2005) Memory-related hippocampal dysfunction in polydrug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology 180: 607-611
34. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E (2004) Self-reported psychopathological symptoms in abstinent recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology 173: 398-404
35. Daumann J, Schnitker R, Weidemann J, Schnell K, Thron A, Gouzoulis-Mayfrank E (2003) Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users. Neuro Report 14: 1983-1987
36. Davison D, Parrott A C (1997) Ecstasy in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 12: 91-97
37. DAWN (2000) Club drugs. The Drug Abuse Warning Network (DAWN) report. USA Department of Health and Human Services, Rockville, MD, December
38. De la Torre R, Farre M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25: 505-508
39. De la Torre R, Farre M, O Mathuna B, Roset PN, Pizarro N, Segura M, Torrens M, Ortuno J, Pujadas M, Cami J (2005) MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol 61: 551-554
40. Dittrich A (1994) Psychological aspects of altered states of consciousness of the LSD type. In Pletscher A, Ladewig D (eds), Fifty Years of LSD: Current Status and Future Perspectives of Hallucinogens. Parthenon Publishing, New York, pp. 101-118
41. Doblin R (2002) A clinical plan for MDMA (Ecstasy) in the treatment of Posttraumatic Stress Disorder (PTSD): partnering with the FDA. J Psychoact Drugs 34: 185-194
42. Downing J (1986) The psychological and physiological effects of MDMA in normal volunteers. J Psychoact Drugs 18: 335-339
43. Fisk J E, Montgomery C, Wareing M, Murphy P N. (2005) Reasoning deficits in ecstasy (MDMA) polydrug users. Psychopharmacology (epub ahead of print)
44. Fox H, Parrott A C, Turner J J D (2001) ecstasy/MDMA related cognitive deficits: a function of dosage rather than awareness of problems. J Psychopharmacol 15: 273-281
45. Fox H C, McLean A, Turner J J D, Parrott A C, Rogers R, Sahakian B J (2002) Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ('ecstasy') polydrug users. Psychopharmacology 162: 203-214
46. Freedman R R, Johanson C E, Tancer M E (2005) Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 183: 248-256
47. Gamma A, Buck A, Berthold T, Vollenweider F X (2001) No difference in brain activation during cognitive performance between Ecstasy (3,4- methylenedioxymethamphetamine) users and control subjects: a positron emission tomography study. J Clin Psychopharmacol 21: 66-71
48. Gerra G, Bassignana S, Zaimovic A, Moi G, Bussandri M, Caccavari T, Brambilla F, Molina E (2003) Hypothalamic-pituitary-adrenal axis responses to stress in subjects with 3,4-methylenedioxymethamphetamine ('ecstasy') use high correlation with dopamine receptor sensitivity. Psychiat Res 30: 115-124
49. Gordon C J, Watkinson W P, O'Callaghan J P, Miller D B (1991) Effects of 3,4-methylenedioxymethamphetamine on thermoregulatory responses in the rat. Pharmacol Biochem Behav 38: 339-344
50. Gouzoulis-Mayfrank E, Becker S, Pelz S, Tuchtenhagen F, Daumann J (2002) Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis? Biol Psychiatry 5: 766-769
51. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J (2003) Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuro-Psychopharmacol Biol Psychiat 27: 819-827
52. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert H J, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) J Neurol Neurosurg Psychiat 68: 719-725
53. Gouzoulis-Mayfrank E, Daumann J (2006) The confounding problem of polydrug use in recreational ecstasty/MDMA users: a brief overview. J Psychopharmacol 20: 187-192
54. Green A R, Mechan A O, Elliott J M, O'Shea E, Colado M I (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') Pharmacol Revs 55: 463-508
55. Green A R, Sanchez V, O'Shea E, Saadat K S, Elliott J M, Colado M I (2004) Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. Psychopharmacology 173: 264-269
56. Grundy R I, Rabuffetti M, Beltramo M (2001) Cannabinoids and neuroprotection. Mol Neurobiol 24: 29-51
57. Gunn J, Gurd M (1940) The action of some amines related to adrenaline. Cyclohexylalkylamines. J Physiol 97: 453-470
58. Hall W, Solowij N (1998) The adverse effects of cannabis. Lancet 352: 1611-1616
59. Halpern J H, Pope H G, Sherwood A R, Barry S, Hudson J I, Yurgelun- Todd D (2004) Residual effects of illicit 3,4-methylenedioxymethamphetamine in individuals with minimal exposure to other drugs. Drug and Alcohol Dependence
60. Hampson A J, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J (2000) Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 899: 274-282
61. Hansen D, Maycock B, Lower T (2001) 'Weddings, parties, anything, a qualitative analysis of ecstasy use in Perth, Western Australia. Int J Drug Policy 12: 181-199
62. Hanson K L, Luciana M (2004) Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med 34: 229-46
63. Heffernan T M, Ling J, Parrott A C, Buchanan T, Scholey A B, Rodgers J (2005) Self-rated everyday and prospective memory abilities of cigarette smokers and non-smokers: a web based study. Drug Alc Depend 78: 235-241
64. Hegadoren K M, Baker G B, Bourin M (1998) 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Revs 23: 539-553
65. Henry J A, Jeffries K J, Dawling S (1992) Toxicity and deaths from 3,4- methylenedioxymethamphetamine ('Ecstasy'). Lancet 340: 384-387
66. Hernandez-Lopez C, Farre M, Roset P N, Menoyo E, Pizarro N, Ortuno J, Torrens M, Cami J, de La Torre R (2002) 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300: 236-244
67. Huether G, Zhou D, Ryuther E (1997) Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') and its congeners. J Neural Transmiss 104: 771-794
68. Jacobsen L K, Mencl W E, Pugh K R, Skudlarski P, Krystal J H (2004. Preliminary evidence of hippocampal dysfunction in adolescent MDMA ('ecstasy') users: possible relationship to neurotoxic effects. Psychopharmacology 173: 383-390
69. Jansen K L R (1999) ecstasy (MDMA) dependence. Drug Alc Dep 53: 121-124
70. Kopelman M D, Reed L J, Marsden P, Mayes A R, Jaldow E, Laing H, Isaac C (2001) Amnesic syndrome and severe ataxia following the recreational use of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and other substances. Neurocase 7: 423-432
71. Laviola G, Adriani W, Terranova M L, Gerra G (1999) Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neurosci Biobehav Rev 23: 993-1010
72. Lieb R, Schuetz C G, Pfister H, von Sydow K, Wittchen H-U (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alc Dep 68: 195-207
73. Liechti M E, Gamma A, Vollenweider F X (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154: 161-168
74. Ling J, Heffernan T M, Buchanan T, Rodgers J, Scholey A B, Parrott A C (2003) Effects of alcohol on subjective ratings of prospective and everyday memory deficits. Alcoholism Clin Exp Res 27: 970-974
75. Lynch W J, Roth M E, Carroll M E (2002) Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology 164: 121-137
76. M ter Bogt T F, Engels R C. (2005) 'Partying' hard: party style, motives for and effects of MDMA use at rave parties. Subst Use Misuse 40: 1479-1502
77. McCann U D, Ricaurte G A (1991) Lasting neuropsychiatric sequelae of (-/-)methylenedioxymethamphetamine ('ecstasy') in recreational users. J Clin Psychopharmacol 11: 302-305
78. McCann U D, Eligulashvili V, Ricaurte G A (2000) 3,4- methylenedioxymethamphetamine ('Ecstacy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42: 11-16
79. McCann U D, Mertl M, Eligulashvili V, Ricaurte G A (1999) Cognitive performance in (-/-)3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users: a controlled study. Psychopharmacology 143: 417-425
80. McCardle K, Luebbers S, Carter J D, Croft R J, Stough C (2004) Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology 173: 434-439
81. McGregor I S, Gurtman C G, Morley K C, Clemens K J, Blokland A, Li K M, Cornish J L, Hunt G E (2003) Increased anxiety and depressive symptoms months after using MDMA ('ecstasy') in rats: drug induced hyperthermia does not predict long term outcomes. Psychopharmacology 168: 465-478
82. McGuire P (2000) Long term psychiatric and cognitive effects of MDMA use. Toxicol Lett 112: 153-156
83. MacInnes N, Handley S L, Harding G F A (2001) Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 15: 181-186
84. Malberg J E, Seiden L S (1998) Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18: 5086-5094
85. Mas M, Farre M, de la Torre R, Roset P N, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290: 136-145
86. Mejias S, Rossignol M, Debatisse D, Streel E, Servais L, Guerit J M, Philippot P, Campanella S (2005) Event-related potentials in ecstasy (MDMA) users during a visual oddball task. Biol Psychol 69: 333-352
87. Milani R M, Parrott A C (2004) Psychological problems may be associated with ecstasy dependence rather than ecstasy lifetime dose. World J Biol Psychiat 5: 130
88. Milani R M, Parrott A C, Schifano F, Turner J J D (2005) Patterns of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms. Hum Psychopharmacol 20: 1-13
89. Milani R, Turner J J D, Parrott A C, Parmar R (2000) Recreational drug use and psychobiological problems, collaborative UK/Italy study (5): ecstasy (MDMA) polydrug findings. J Psychopharmacol 14: a15
90. Monroe S M, Simmons D (1991) Diathesis-Stress theories in the context of life stress research. Psychol Bull 110: 406-425
91. Morgan M J (1999) Memory deficits associated with recreational use of 'ecstasy' (MDMA). Psychopharmacology 141: 30-36
92. Morgan M J (2000) ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152: 230-248
93. Morgan M J, McFie L, Fleetwood L H, Robinson J A (2002) ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159: 294-303
94. Morley K C, Li K M, Hunt G E, Mallet P E, McGregor I S (2004) Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ('ecstasy') in rats. Neuropharmacology 46: 954-965
95. Morton A J, Hickey M A, Dean L C (2001) Methamphetamine toxicity is potentiated by exposure to loud music. Neuroreport 12: 3277-3281
96. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset P N, Palmi I, Ortuno J, Menoyo E, Segura J, de la Torre R (2002) Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus non-controlled settings. Ann N Y Acad Sci 965: 421-433
97. Parrott A C (1999) Does cigarette smoking cause stress? Amer Psychol 54: 817-820
98. Parrott A C (2000) Human research on MDMA (3,4- methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 42: 17-24
99. Parrott A C (2001) Human psychopharmacology of ecstasy (MDMA): a review of fifteen years of empirical research. Hum Psychopharmacol 16: 557-577
100. Parrott A C (2002) Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71: 837-844
101. Parrott A C (2003a) Cognitive deficits and cognitive normality in recreational cannabis and ecstasy/MDMA users. Hum Psychopharmacol 18: 89-90
102. Parrott A C (2003b) Cigarette-derived nicotine is not a medicine. World J Biol Psychiatry 4(2): 49-55
103. Parrott A C (2004a) Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, dosage levels, and the changing perceptions of purity. Psychopharmacology 173: 234-241
104. Parrott A C (2004b) MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 50: 329-335
105. Parrott A C (2005) Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or ecstasy. J Psychopharm 19: 71-83
106. Parrott A C, Lasky J (1998) ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology 139: 261-268
107. Parrott A C, Kaye F J (1999) Daily uplifts, hassles, stresses and cognitive failures: in cigarette smokers, abstaining smokers, and non-smokers. Behav Pharmacol 10: 639-646
108. Parrott A C, Young L (2005) Increased body temperature in recreational ecstasy/MDMA users out clubbing and dancing, J Psychopharmacol 19: a26
109. Parrott A C, Sisk E, Turner J (2000) Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alc Depend 60: 105-110
110. Parrott A C, Gouzoulis-Mayfrank E, Rodgers J, Solowij N (2004a) ecstasy/MDMA and cannabis: the complexities of their interactive neuropsychobiological effects. J Psychopharmacol 18: 579-582
111. Parrott A C, Margetson J, Thome J, Christian (2005a) Cigarettes, ecstasy and the inverse of pleasure: nicotine abstinence effects in recreational ecstasy/MDMA users. J Psychopharm 19: a27
112. Parrott A C, Milani R, Parmar R, Turner J J D (2001) ecstasy polydrug users and other recreational drug users in Britain and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159: 77-82
113. Parrott A, Morinan A, Moss M, Scholey A (2004b) Understanding Drugs and Behaviour. Wiley, Chichester
114. Parrott A C, Lees A, Garnham N J, Jones M, Wesnes K (1998) Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits. J Psychopharmacol 12: 79-83
115. Parrott A C, Buchanan T, Scholey A B, Heffernan T M, Ling J, Rodgers J (2002) ecstasy attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 17: 309-312
116. Parrott A C, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey A B (2005b) Prospective memory problems in recreational MDMA users: relationship to dancing and feeling hot when on ecstasy. J Psychopharm 19: a57
117. Pedersen W, Skrondal A (1999) ecstasy and new patterns of drug use: a normal population study. Addiction 94: 1695-1706
118. Peroutka S J, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1: 273-277
119. Pope H G, Gruber A J, Hudson J I, Huestis M A, Yurgelun-Todd D (2001) Neuropsychological performance in long-term cannabis users. Arch Gen Psychiat 58: 909-915
120. Quednow B B, Kuhn K U, Hoenig K, Maier W, Wagner M (2004) Prepulse inhibition and habituation of acoustic startle response in male MDMA ('ecstasy') users, cannabis users, and healthy controls. Neuropsychopharmacology 29: 982-990
121. Reneman L, Schilt T, de Win M M, Bouij J, Schmand B, van den Brink W, Bakker O (2006) Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. J Psychopharmoacol (in press)
122. Renfroe C L (1986) MDMA on the street: analysis anonymous. J Psychoact Drugs 18: 363-369
123. Ricaurte G A, McCann U D (2001) Experimental studies on 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its potential to damage brain serotonin neurons. Neurotox Res 3: 85-99
124. Ricaurte G A, Yuan J, McCann U D (2000) (-/-)3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42: 5-10
125. Ricaurte G A, Bryan G, Strauss L, Seiden L S, Schuster C R (1985) Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229: 986-988
126. Riley S C E, James C, Gregory D, Dingle H, Cadger M (2001) Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction 96: 1035-1047
127. Rizzo M, Lamers C T J, Sauer C G, Ramaekers J G, Bechara A, Anderson G J (2005) Impaired perception of self-motion (heading) in abstinent ecstasy and marijuana users. Psychopharmacology 179: 559-566
128. Rodgers J (2000) Cognitive performance amongst recreational users of 'ecstasy'. Psychopharmacology 151: 19-24
129. Rodgers J, Buchanan T, Scholey A B, Heffernan T M, Ling J, Parrott A C (2003) Patterns of drug use and the influence of gender on self reports of memory ability in ecstasy users: a web based study. J Psychopharmacol 17: 379-386
130. Roiser J P, Sahakian B J (2004) Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology 173: 411-417
131. Roiser J P, Cook L J, Cooper J D, Rubinsztein D C, Sahakian B J (2005) Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Am J Psychiat 162: 609-612
132. Schifano F (2000) Potential human neurotoxicity of MDMA ('ecstasy') subjective self-reports, evidence form an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42: 25-33
133. Schifano F, Magni G (1994) MDMA ('ecstasy') abuse: psychopathological features and craving for chocolate: a case series. Biol Psychiat 36: 763-767
134. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R (1998) MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alc Depend 52: 85-90
135. Schifano F, Corkesy J, Deluca P, Oyefaso A, Ghodse A H (2006) Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures related offences, prices, dosage levels and deaths in the UK (1994-2003). J Psychopharmacol (in press)
136. Scholey A B, Parrott A C, Buchanan T, Heffernan T, Ling J, Rodgers J (2004) Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: a www study. Addictive Behav 29: 743-752
137. Schuster P, Lieb R, Lamertz C, Wittchen H U (1998) Is the use of ecstasy and hallucinogens increasing? Eur Addict Res 4: 75-82
138. Simantov R, Peng W (2004) MDMA (ecstasy) controls in concert a group of genes involved in GABA neurotransmission. Fed Eur Biochem Soc Lett 563: 3-6
139. Simon N G, Mattick R P (2002) The impact of regular ecstasy use on memory function. Addiction 97: 1523-1529
140. Singer L T, Linares T J, Ntiri S, Henry R, Minnes S (2004) Psychosocial profiles of older adolescent MDMA users. Drug Alc Depend 74: 245-252
141. Soar K, Parrott A C, Turner J J D, (2004) Persistent neuropsychological problems after seven years of abstinence from recreational ecstasy (MDMA): a case study. Psychol Reps 95: 192-196
142. Soar K, Parrott A C, Turner J J D, (2005) No more the 'love drug': sexual behaviour impairments in ecstasy users. J Psychopharmacol 19: a25
143. Soar K, Turner J J D, Parrott A C, (2001) Psychiatric disorders in recreational ecstasy (MDMA) users: a literature review focusing upon personal predisposition factors and drug histories. Hum Psychopharmacol 16: 641-646
144. Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of ecstasy users and their experiences with the drug. Br J Addict 87: 1161-1172
145. Spruit I P (2001) Monitoring synthetic drug markets, trends and public health. Substance Use Misuse 36: 23-47
146. Strote J, Lee J E, Wechsler H (2002) Increasing MDMA use among college students: results of a national survey. J Adolesc Health 30: 64-72
147. Sumnall H R, Cole J C (2005) Self-reported depressive symptomatology in community samples of polysubstance misusers who report ecstasy use: a meta-analysis. J Psychopharmacol 19: 84-92
148. Sumnall H R, Wagstaff G F, Cole J C (2004) Self-reported psychopathology in polydrug users. J Psychopharmacol 18: 75-82
149. Suy K, Gijsenbergh F, Baute L (1999) Emergency medical assistance during a mass gathering. Eur J Emerg Med 6: 249-254
150. Tancer M E, Johanson C E, Freedman R R (2003) MDMA elevates core temperature in warm and cold conditions in man. College on Problems of Drug Dependence Annual Conference. Florida USA, June 2003. Conference Abstract, p. 169
151. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 167: 85-96
152. Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A (2006) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 20: 210-214
153. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) ecstasy use in Australia: patterns of use and associated harm. Drug Alc Depend 55: 105-115
154. Tossman P, Boldt S, Tensil M D (2001) The use of drugs within the techno party scene in European metropolitan cities. Addiction Res 7: 2-23
155. Tuchenhagen F, Daumann J, Norra C, Gobbele R, Becker S, Pelz S, Sass H, Buchner H, Gouzoulis-Mayfrank E (2000) High intensity dependence of auditory evoked dipole source activity indicates decreased serononergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology 22: 608-617
156. Verheyden S L, Henry J A, Curran H V (2003a) Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol 18: 507-517
157. Verheyden S L, Maidment R, Curran H V (2003b) Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. J Psychopharmacol 371-378
158. Verheyden S L, Hadfield J, Calin T, Curran H V (2002) Sub-acute effects of MDMA (-/-3,4-methylenedioxymethamphetamine, 'ecstasy') on mood: evidence of gender differences. Psychopharmacology 161: 23-31
159. Verkes R J, Gigsman H J, Pieters M S M, Schoemaker R C, de Visser S, Kuijpers M (2001) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 53: 196-202
160. Vollenweider F X, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241-251
161. Vollenweider F X, Liechti M E, Gamma A, Greer G, Geyer M (2002) Acute psychological and neurophysiological effects of MDMA in humans. J Psychoactive Drugs 34: 171-184
162. Von Geusau A, Stalenhoef P, Huizinga M, Snel J, Ridderinkher K R (2004) Impaired executive function in male MDMA (ecstasy) users. Psychopharmacology
163. Wareing M, Fisk J E, Murphy P N (2000) Working deficits in current and previous users of MDMA ('ecstasy'). Br J Psychol 91: 181-188
164. Wareing M, Murphy P N, Fisk J E (2004) Visuospatial memory impairments in users of MDMA ('ecstasy'). Psychopharmacology 173: 391-397
165. Webb E, Ashton C H, Kelly P, Kamali F (1996) Alcohol and drug use in UK university students. Lancet 348: 922-925
166. Wijngaart van de G M, Braam R, de Bruin M, Fris M, Maalste N J M, Verbraeck H T (1999) ecstasy and the Dutch rave scene: a socio-epidemiological study. J Drug Issues 19: 697-702
167. Williamson S, Gossop M, Powis B, Griffiths P, Fountain J, Strang J (1997) Adverse effects of stimulant drugs in a community sample of drug users. Drug Alc Depend 44: 87-94
168. de Win M M, Reneman L, Reitsma J B, den Heeten G J, Booij J, van den Brink W (2004) Mood disorders and serotonin transporter density in ecstasy users-the influence of long-term abstention, dose and gender. Psychopharmacology 173: 376-382
169. Winstock A R, Griffiths P, Stewart D (2001) Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alc Depend 64: 9-17
170. Yacoubian G S, Boyle C, Harding C A, Loftus E A (2003) It's a rave new world: estimating the prevalence and perceived harm of ecstasy and other drug use among club rave attendees. J Drug Educ 33: 187-196
171. Yip J, Lee T (2005) The effects of ecstasy use on neuropsychological function: a study in Hong Kong. Psychopharmacology 179: 620-628
172. Young J M, McGregor I S, Mallet P E. (2005) Co-administration of THC and MDMA ('ecstasy') synergistically disrupts memory in rats. Neuropsychopharmacology 30: 1475-1482
173. Zakzanis K K, Young D A (2001) Memory impairment in abstinent MDMA ('ecstasy') users: a longitudinal investigation. Neurology 56: 966-969
174. Zhou J F, Chen P, Zhou Y H, Zhang L, Chen H H (2003) 3,4- methylenedioxymethamphetamine abuse may cause oxidative stress and potential free radical damage. Free radical Res 37: 491-497